Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Impressive Q2 Performance Drives Further Guidance Raise At ANI
Firm Now Anticipates 2023 Net Revenue Between $425m And $445m
Aug 22 2023
•
By
Chloe Kent
ANI's performance was driven by generic products and Cortrophin gel • Source: Shutterstock
More from Earnings
More from Business